FREE TREATMENT REPORT
See ratings and reviews when you sign up for an account.
Attention & Memory Impairments in Menopausal Women: A Possible Role for Vyvanse?
This study is currently Recruiting
February 2011 By University of Pennsylvania
First Recieved on March 24, 2011
Last Updated on March 25, 2011
The purpose of this study is to determine whether a medication called Vyvanse?
(lisdexamfetamine; LDX) has an impact on cognitive functioning, specifically measures of
sustained attention, verbal encoding and recall and working memory, in menopausal aged
women. LDX is a medication used to treat attention deficit hyperactivity disorder (ADHD).
The cognitive difficulties that menopausal women report experiencing are typical of adults
who are diagnosed with ADHD. The investigators will assess whether or not LDX is effective
in alleviating those cognitive disruptions when compared to a placebo.
||Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Resources/Links provided by NLM:
|Study Start Date:
|Estimated Primary Completion Date:
|Sugar Pill:Placebo Comparator|
The purpose of this study is to assess whether or not lisdexamfetamine is effective in alleviating cognitive disruptions when compared to a placebo.
|Ages Eligible for Study:||45 Years|
|Genders Eligible for Study:||Female|
|Accepts Healthy Volunteers:||Accepts Healthy Volunteers|
Women ages 45 to 57 will be eligible for this study if they:
- Are within 5 years of their last menstrual period;
- Are able to give written informed consent;
- Must have clear urine toxicology screen upon recruitment;
- Are fluent in written and spoken English;
- Must have negative urine pregnancy test if still menstruating.
- History of seizures;
- History of cardiac disease including known cardiac defect or conduction abnormality;
- Abnormal electrocardiogram during screening;
- Use of estrogen therapy within previous 6 months;
- Current pregnancy or planning to become pregnant.
- Presence of a contraindication to treatment with stimulant medication; this would
include the presence of hypertension, coronary disease, atrial fibrillation, and
- Investigator: C. Neill Epperson, MD - Principal Investigator - University of Pennsylvania